EA200200548A1 - Способ получения антагонистов альфа-v-интегрина на основе имидазолидинона и промежуточные соединения для их получения - Google Patents

Способ получения антагонистов альфа-v-интегрина на основе имидазолидинона и промежуточные соединения для их получения

Info

Publication number
EA200200548A1
EA200200548A1 EA200200548A EA200200548A EA200200548A1 EA 200200548 A1 EA200200548 A1 EA 200200548A1 EA 200200548 A EA200200548 A EA 200200548A EA 200200548 A EA200200548 A EA 200200548A EA 200200548 A1 EA200200548 A1 EA 200200548A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obtaining
imidazolidinone
integrine
antagonists
alpha
Prior art date
Application number
EA200200548A
Other languages
English (en)
Inventor
Марк С. Дженсен
Майкл Палуки
Нело Р. Ривера
Кеннет М. Уэллс
Йи Ксиао
Ялинг Ванг
Чунхуа Янг
Нобуйоси Ясуда
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA200200548A1 publication Critical patent/EA200200548A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к новому способу получения антагонистов αvβ3/αvβ5-интегрина на основе имидазолидинона и промежуточных соединений, используемых для их получения. Указанные соединения являются антагонистами рецепторов αvβ3/αvβ5-интегрина, поэтому их можно эффективно использовать для ингибирования резорбции костей, а также для лечения и профилактики остеопороза. Объектом настоящего изобретения является также 3-{2-оксо-3-[3-(5,6,7,8-тетрагидро[1,8]нафтиридин-2-ил)пропил]имидазолидин-1-ил}-3(S)-(6-метоксипиридин-3-ил)пропионовая кислота в форме полугидрата.Отчет о международном поиске был опубликован 2002.01.17.
EA200200548A 1999-11-08 2000-11-03 Способ получения антагонистов альфа-v-интегрина на основе имидазолидинона и промежуточные соединения для их получения EA200200548A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16397999P 1999-11-08 1999-11-08
PCT/US2000/030361 WO2001034602A2 (en) 1999-11-08 2000-11-03 Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists

Publications (1)

Publication Number Publication Date
EA200200548A1 true EA200200548A1 (ru) 2002-10-31

Family

ID=22592461

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200548A EA200200548A1 (ru) 1999-11-08 2000-11-03 Способ получения антагонистов альфа-v-интегрина на основе имидазолидинона и промежуточные соединения для их получения

Country Status (20)

Country Link
EP (1) EP1230240B1 (ru)
JP (1) JP2003513974A (ru)
KR (1) KR20020048427A (ru)
CN (1) CN1414966A (ru)
AR (1) AR029407A1 (ru)
AT (1) ATE245645T1 (ru)
AU (1) AU777919B2 (ru)
BR (1) BR0015384A (ru)
CA (1) CA2389999A1 (ru)
CZ (1) CZ20021508A3 (ru)
DE (1) DE60004087T2 (ru)
EA (1) EA200200548A1 (ru)
ES (1) ES2202191T3 (ru)
HU (1) HUP0203246A3 (ru)
IL (1) IL149313A0 (ru)
MX (1) MXPA02004547A (ru)
PL (1) PL355011A1 (ru)
SK (1) SK8012002A3 (ru)
WO (1) WO2001034602A2 (ru)
YU (1) YU32502A (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421792A1 (en) * 2000-09-13 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
US20040254211A1 (en) 2000-09-14 2004-12-16 Arison Byron H Alpha v integrin receptor antagonists
US6706885B2 (en) 2001-06-06 2004-03-16 Merck & Co., Inc. Process for preparing integrin antagonist intermediates
US6509347B2 (en) 2001-06-11 2003-01-21 Merck & Co., Inc. Crystalline forms of an integrin receptor antagonist
US6646130B2 (en) 2001-07-19 2003-11-11 Merck & Co., Inc. Process to chiral integrin antagonist beta-amino acid intermediate
AR038189A1 (es) * 2002-01-29 2005-01-05 Merck & Co Inc Proceso para la preparacion de intermediarios de antagonistas de integrina
US20060030581A1 (en) * 2002-09-20 2006-02-09 Debusi Laura A Mannitol formulation for integrin receptor antagonist
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
DK3929196T3 (da) 2013-09-24 2023-09-25 Fujifilm Corp Farmaceutisk sammensætning af en nitrogenholdig forbindelse eller salt deraf, eller metalkompleks deraf
AP2016009156A0 (en) * 2013-10-25 2016-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2016054483A1 (en) * 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CA3042693A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Pyrrole amides as .alpha.v integrin inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003095B1 (ru) * 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов

Also Published As

Publication number Publication date
HUP0203246A3 (en) 2003-12-29
BR0015384A (pt) 2002-10-08
IL149313A0 (en) 2002-11-10
MXPA02004547A (es) 2002-09-02
CZ20021508A3 (cs) 2002-10-16
ATE245645T1 (de) 2003-08-15
DE60004087D1 (de) 2003-08-28
DE60004087T2 (de) 2004-04-15
EP1230240B1 (en) 2003-07-23
YU32502A (sh) 2004-12-31
SK8012002A3 (en) 2002-10-08
AU1461401A (en) 2001-06-06
JP2003513974A (ja) 2003-04-15
AU777919B2 (en) 2004-11-04
ES2202191T3 (es) 2004-04-01
WO2001034602A3 (en) 2002-01-17
AR029407A1 (es) 2003-06-25
KR20020048427A (ko) 2002-06-22
HUP0203246A2 (hu) 2003-01-28
CA2389999A1 (en) 2001-05-17
CN1414966A (zh) 2003-04-30
EP1230240A2 (en) 2002-08-14
PL355011A1 (en) 2004-03-22
WO2001034602A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
EA200200548A1 (ru) Способ получения антагонистов альфа-v-интегрина на основе имидазолидинона и промежуточные соединения для их получения
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
EP0403158A3 (en) Imidazolyl-alkenoic acids
SK5562003A3 (en) EP4 receptor selective agonists in the treatment of osteoporosis
PH27592A (en) Imidazolyl-alkenoic acids and its method of use
ES2195943T3 (es) Compuestos heteroaromaticos biciclicos y triciclicos.
EA200300065A1 (ru) Окисленные сложные эфиры 4-йодфениламинобензгидроксамовых кислот
MX9702070A (es) Nuevos inhibidores de resorcion osea y antagonistas de receptor de vitronectina.
PT894084E (pt) Derivados de acido cinamico e sua utilizacao como antagonistas de integrina
EA200000358A1 (ru) Способ получения диарилпиридинов, полезных в качестве ингибиторов cox-2
EA199800873A1 (ru) Дигидрат эпросартана и способ его получения и готовая препаративная форма
EP0853084A3 (de) Substituierte Purinderivate als Vitronectinrezeptor-Antagonisten
MXPA04003192A (es) Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas.
DE60117963D1 (de) Verfahren zu herstellung von citalopram
BR9815296A (pt) Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
EE03003B1 (et) Angiotensiin II retseptorite antagonistidena toimivad triasolopürimidiinide derivaadid, ravimvormid, nende valmistamise meetodid
ZA200200082B (en) Preparation of chemical pulp and xylose, utilizing a direct acid hydrolysis on the pulp.
IL153200A0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A gOBG3
BR0315375A (pt) Processo para a preparação conjunta de compostos
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
EE03046B1 (et) Angiotensiin II retseptorite antagonistide triasolopürimidiinide derivaadid, nende valmistamise meetod ja ravimvormid
WO2001081298A3 (en) Cyclic carboxylic acids as integrin antagonists
IT1297034B1 (it) Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
ATE294790T1 (de) Chlormethylierung von thiophene